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Abstract
OBJECTIVES—The purpose of this study was to assess the phenotype of Filamin C (FLNC) 
truncating variants in dilated cardiomyopathy (DCM) and understand the mechanism leading to an 
arrhythmogenic phenotype.
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BACKGROUND—Mutations in FLNC are known to lead to skeletal myopathies, which may 
have an associated cardiac component. Recently, the clinical spectrum of FLNC mutations has 
been recognized to include a cardiac-restricted presentation in the absence of skeletal muscle 
involvement.
METHODS—A population of 319 U.S. and European DCM cardiomyopathy families was 
evaluated using whole-exome and targeted next-generation sequencing. FLNC truncation probands 
were identified and evaluated by clinical examination, histology, transmission electron 
microscopy, and immunohistochemistry.
RESULTS—A total of 13 individuals in 7 families (2.2%) were found to harbor 6 different FLNC 
truncation variants (2 stopgain, 1 frameshift, and 3 splicing). Of the 13 FLNC truncation carriers, 
11 (85%) had either ventricular arrhythmias or sudden cardiac death, and 5 (38%) presented with 
evidence of right ventricular dilation. Pathology analysis of 2 explanted hearts from affected 
FLNC truncation carriers showed interstitial fibrosis in the right ventricle and epicardial fibrofatty 
infiltration in the left ventricle. Ultrastructural findings included occasional disarray of Z-discs 
within the sarcomere. Immunohistochemistry showed normal plakoglobin signal at cell–cell 
junctions, but decreased signals for desmoplakin and synapse-associated protein 97 in the 
myocardium and buccal mucosa.
CONCLUSIONS—We found FLNC truncating variants, present in 2.2% of DCM families, to be 
associated with a cardiac-restricted arrhythmogenic DCM phenotype characterized by a high risk 
of life-threatening ventricular arrhythmias and a pathological cellular phenotype partially 
overlapping with arrhythmogenic right ventricular cardiomyopathy.
Keywords
arrhythmias; arrhythmogenic dilated cardiomyopathy; cardiovascular genetics; Filamin C; familial 
dilated cardiomyopathy; heart failure
Dilated cardiomyopathy (DCM) is a major cause of heart failure and disproportionately 
leads to cardiac transplantation (1–3). The condition is familial in ~50% of cases, and 
genetic variants residing in over 40 genes have been found to cause DCM through a variety 
of pathological mechanisms associated with perturbations of the cytoskeleton, intercalated 
disc region, nuclear envelope, and muscle sarcomere (1,3). Filamin C (FLNC) is an actin 
cross-linking protein (4) that provides structure for the sarcomere and is one of the largest Z-
disc proteins (2,725 amino acids) in cardiac and skeletal muscle. FLNC also localizes to the 
sarcolemma, where it connects the muscle cell to the extra-cellular matrix and is involved in 
related signaling pathways (5).
Originally, FLNC gene mutations were associated with distal and myofibrillar skeletal 
myopathies (MFM) (6), characterized by loss of myofibrils and filamentous intracellular 
aggregates of myocyte proteins, including desmin, dystrophin, and sarcoglycans. Further 
investigations have revealed that FLNC missense mutations may lead to hypertrophic 
cardiomyopathy (HCM) (7) and restrictive cardiomyopathy (RCM) (8). Recently, using 
whole exome sequencing, we identified an FLNC splicing variant as causing DCM in the 
absence of skeletal muscle involvement in 2 families (9), a finding further supported by the 
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report of FLNC truncation variants in 4% of DCM and 3% of arrhythmogenic DCM patients 
(10–12).
In the current study, we report the characterization of the clinical features of FLNC 
truncating variant carriers, which include a prominent arrhythmogenic DCM phenotype (13), 
sarcomere structural changes by transmission electron microscopy (TEM), and changes in 
the distribution of cell–cell junction proteins in the myocardium and buccal mucosa. These 
structural and cellular changes overlap with arrhythmogenic right ventricular 
cardiomyopathy (ARVC), and represent a critical link between DCM and ARVC, leading to 
a more comprehensive understanding of complex familial arrhythmia syndromes as well as 
an appreciation of the need for mutation-directed clinical monitoring and treatment of this 
population.
METHODS
STUDY POPULATION AND CARDIOMYOPATHY EVALUATION
We analyzed 319 U.S. and European DCM families from the Familial Cardiomyopathy 
Registry. Study subjects underwent extensive clinical evaluations (details in the Online 
Appendix) (14). Medical records from deceased subjects were reviewed when available (9). 
Informed consent was obtained from living subjects, and local institutional review boards 
approved the study protocols.
NEXT-GENERATION SEQUENCING AND BIOINFORMATIC ANALYSIS
Twenty larger families were evaluated by whole-exome sequencing (9). In 299 smaller 
families, probands were evaluated using the Illumina TruSight One-Sequence panel 
(Illumina, Redwood City, California), which queries 4,813 genes associated with known 
clinical phenotypes (15). Briefly, subject deoxyribonucleic acid (DNA) was captured with 
the panel, sequenced on an HISEQ 2500 (Illumina) with v4 chemistry, and mapped with 
Genomic Short-read Nucleotide Alignment Program (version 2012-07-20) (16). Variants 
were called with the Genome Analysis Toolkit (version 2.1-8-g5efb575, Broad Institute, 
Cambridge, Massachusetts) and classified with Annovar (version 2012-07-28) (17). 
Functional predictions were made with the database for Nonsynonymous SNPs and Their 
Functional Predictions (version 2.0) (18). All variants were confirmed by Sanger sequencing 
(19). Variants predicted to be damaging in at least 1 of the prediction algorithms were 
retained, whereas missense and truncation variants present in >1% in the 1000 Genomes 
Project were discarded (9,20).
Variant frequency information was obtained from the 6,500 National Human, Lung, and 
Blood Institute Exome Sequencing Project (21) and the Exome Aggregation Consortium 
(ExAC, Cambridge, Massachusetts) (22) on February 27, 2017, and was cross-referenced to 
the ClinVar database (23). Gene variant locations are provided in reference to FLNC 
transcript NM_001458. Cosegregation analysis was performed when DNA from biological 
relatives was available. Variants in other cardiomyopathy-related genes were also identified 
using the Illumina TruSight One Sequencing Panel, as described in the previous text, and 
confirmed using Sanger sequencing.
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HISTOLOGY AND TRANSMISSION ELECTRON MICROSCOPY
Cardiac muscle tissue was obtained from 2 affected siblings of family DNFDC057 (Figure 
1), including left ventricular (LV) tissue at the time of LV assist device placement in subject 
II:1 and LV and right ventricular (RV) tissue from the explanted heart of subject II:2. Fresh 
heart tissue samples were processed according to standard histology protocols for 
hematoxylin and eosin, Masson’s trichrome, and immunohistochemistry staining and fixed 
for TEM. Details can be found in the Online Appendix.
IMMUNOSTAINING
Cotton-tipped swabs (Medi-Choice, Mechanicsville, Virginia) were used to collect buccal 
mucosa cells from 2 siblings with truncating variants in FLNC and from normal control 
subjects. Each cheek was rubbed with a slight rolling and scraping motion, and the resulting 
material was smeared on standard microscope slides. Immunostaining of buccal mucosa and 
myocardial tissue was performed as previously described (24), and is detailed in the Online 
Appendix. For immunofluorescence microscopy, antibodies included: mouse monoclonal 
antiplakoglobin (P8087, Sigma-Aldrich, St. Louis, Missouri), mouse monoclonal anti–
connexin 43 (Cx43) (Millipore, Burlington, Massachusetts), mouse monoclonal anti–N-
cadherin (Sigma-Aldrich), mouse monoclonal antidesmoplakin (Fitzgerald, Acton, 
Massachusetts), mouse monoclonal anti–synapse-associated protein 97SAP97 (Santa Cruz, 
Dallas, Texas), and rabbit polyclonal antiglycogen synthase kinase 3β (GSK3β) (Cell 
Signaling Technology, Danvers, Massachusetts). Immunostained preparations were analyzed 
by confocal microscopy (LSM-510, Zeiss, Oberkochen, Germany).
RIBONUCLEIC ACID SEQUENCING OF EXPLANTED HEART TISSUE
Ribonucleic acid (RNA) was extracted from frozen LV tissue using the mirVana miRNA 
isolation kit (Thermo Fisher Scientific, Waltham, Massachusetts) enriched for total RNA 
according to manufacturer’s instructions with the exception of replacing the lysis/binding 
buffer with mechanical homogenization in TRIzol (Thermo Fisher Scientific). The library 
was sequenced 1 × 50 (Illumina HiSeq 2500). Reads were filtered for quality and aligned to 
the GRCh37hg19 reference human genome using the Genomic Short-read Nucleotide 
Alignment Program. Transcripts aligning to FLNC were visualized using the Integrative 
Genomics Viewer (Broad Institute).
RESULTS
IDENTIFICATION OF FLNC TRUNCATIONS
Pathogenic/likely pathogenic variants have been identified in approximately 40% of dilated 
cardiomyopathy samples from the Familial Cardiomyopathy Registry (data not shown), and 
include TTN (11%), sarcomeric genes (10%), structural cytoskeleton genes (5%), LMNA 
(4%), ion channel genes (2%), and other rare genes (5%). A total of 6 FLNC truncation 
variants (Figure 1), including 2 FLNC stopgain (families DNFDC079 and TSSDC130), 1 
frameshift (DNFDC057), and 3 splicing variants (families DNFDC195, TSFDC029, 
TSFDC031, and TSFDC043), were identified in 7 of the 319 DCM families, for an overall 
frequency of 2.2% (7 of 319) (Figure 2, Table 1), 100-fold more frequent than the 0.02% 
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FLNC loss of function variants reported in ExAC (22). Five of the FLNC truncation variants 
were absent from the 1000 Genomes Project, 6,500 Exome Sequencing Project, ExAC, and 
ClinVar databases; c.805C>T had a minor allele frequency of 8.3 × 10−6 in ExAC (Online 
Table 1). FLNC variants p.Y2381Gfs21X and p.G1891Vfs61X have been previously 
reported (9). The 6 FLNC truncation variants reported here (Figures 1 and 2) occur in the 
immunoglobulin domains of the FLNC protein with no apparent geographical clustering or 
relationships to HCM, RCM, and MFM FLNC variants described to date. The presence of a 
secondary “likely pathogenic” unique variant was found in a known cardiomyopathy-related 
gene in the TSFDC043 proband (SCN5A c.5270delT; p.F1757fs, not reported in ExAC and 
ClinVar databases) who did not show signs of Brugada or long QT syndromes. Finally, 
FLNC missense variants detected in the overall population of 319 families are charted to the 
FLNC protein in Online Figure 1 and details are reported in Online Table 2.
RNA-Seq was performed on the explanted heart of DNFDC057 patient II:2. The majority of 
FLNC transcripts (141 of 162 total reads; 87.0%) were wildtype, and the remaining reads 
predominantly contained the c.5669-1delG, resulting in a frameshift and subsequent 
premature stop codon (as nucleotide 5670 is also a G, splicing occurs normally but 
introduces a frameshift into exon 34). These data support a mechanism of nonsense-
mediated decay leading to haploinsufficiency, consistent with our zebrafish studies in which 
morpholino knockdown of the flncb transcript led to a cardiac phenotype.
CLINICAL PHENOTYPES OF FLNC TRUNCATION AFFECTED INDIVIDUALS
Clinical features of FLNC truncation carriers are reported in Table 1, and a detailed clinical 
description is reported in the Online Appendix. None of the patients fulfilled Task Force 
criteria of ARVC (25). Comprehensive physical examination of the skeletal muscle of all 
probands revealed no skeletal muscle abnormalities; serum creatine kinase levels were 
normal in all tested probands.
Supraventricular and ventricular arrhythmias as well as conduction disease were prominent 
clinical features (Figure 1, Table 1). Ventricular arrhythmias appear to originate from the LV 
or appeared polymorphic. Sudden cardiac death (SCD) occurred before the age of 55 years 
in 5 of 22 (23%) confirmed (n = 13) or suspected by family history (n = 9) truncation 
carriers. RV involvement with dilatation and/or dysfunction was present in 5 of 13 (38%) 
cases. The overall penetrance of FLNC truncation variants in our 7 families was 92% (1 
unaffected of 13 total confirmed truncation carriers).
HISTOLOGICAL AND ULTRASTRUCTURAL CARDIAC ANALYSIS OF FLNC G1891Vfs61X 
VARIANT
Cardiac muscle tissue was studied from 2 affected siblings of family DNFDC057. In the 
proband II:2, light microscopic analysis of the LV from the explanted heart showed myocyte 
hypertrophy, diffuse interstitial fibrosis, and focal replacement fibrosis (Figure 3A). 
Epicardial fat tissue infiltrated focally into the LV myocardium, especially in areas of 
replacement fibrosis containing clusters of degenerating myocytes with myofibrillar loss 
(Figure 3A). The RV showed increased interstitial fibrosis and mild fatty infiltration (Figure 
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3B). In the affected sibling II:1, cardiac tissue taken upon LV assist device placement 
showed similar cardiac tissue pathology in the LV (Online Figure 2).
Ultrastructural analysis of LV tissue of affected patient II:1 (DNFDC057) using TEM 
(Figures 4A and 4B) revealed largely normal sarcomere structures, although abnormal Z-
discs were noted. In LV tissue from individual II:2 and II:1 (DNFDC057), the Z-discs 
appeared less compact and diffuse along the Z-disc axis (Figures 4C and 4D). In contrast to 
MFM cases, no intracellular aggregates were seen.
IMMUNOHISTOCHEMICAL ANALYSIS OF FLNC AND ARRHYTHMOGENIC-ASSOCIATED 
PROTEINS
Abnormalities in the distribution and expression of desmosomal and gap junction proteins 
have been reported in cardiac tissue of patients with arrhythmogenic cardiomyopathy (26). 
Because some of the clinical (SCD, ventricular arrhythmia) and structural (RV involvement, 
fibrofatty infiltration) features in our FLNC patients mirrored features of arrhythmogenic 
cardiomyopathy, we used immunohistochemistry to characterize selected protein distribution 
in the LV myocardial tissue in affected individual II:2 of family DNFDC057 (Figure 5).
Immunohistochemistry staining for the desmosomal protein desmoplakin and SAP97, a 
membrane-associated guanylate kinase involved in trafficking sodium and potassium 
channel subunits to the cell surface, revealed overall decreased signal intensity for both of 
these proteins compared with healthy control tissues (Figure 5), agreeing with previous 
studies that showed decreased expression of these proteins in ARVC (27). Additionally, 
staining for GSK3β revealed that this protein retained its cytoplasmic distribution and did 
not translocate to the intercalated discs, which has been shown previously to occur in 
classical ARVC (28). Last, staining for the desmosomal protein plakoglobin and the major 
cardiac gap junction protein Cx43 (normally located in the intercalated discs) revealed these 
proteins to have immunoreactive signals similar in intensity and distribution to the healthy 
control tissues, although the expression of these proteins is usually reduced at cardiac cell–
cell junctions in classical ARVC (26,27). Immunohistochemical staining of FLNC revealed 
no significant intracellular protein aggregates in cardiac myocytes (Figure 6).
Desmosomal and gap junction protein abnormalities have similarly been previously reported 
in the buccal mucosa of patients with ARVC (26), which led us to also perform 
immunostaining of buccal mucosa smears obtained from affected patients DNFDC057 II:1 
and II:2 (Figure 7). Our buccal mucosa cell staining results were generally concordant with 
the LV myocardial immunostaining of patient II:2, including diminished signal intensity for 
desmoplakin and SAP97, and signal intensity near normal levels for plakoglobin. However, 
unlike the normal levels of Cx43 observed in the LV myocardial immunostaining, staining 
for Cx43 was found to be reduced in the buccal mucosa cells.
DISCUSSION
In a cohort of 319 DCM families, prospectively enrolled in the Familial Cardiomyopathy 
Research Registry at the University of Colorado Hospital and Azienda Sanitaria 
Universitaria Integrata of Trieste Hospital, we identified 7 families (2.2%) harboring 6 
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different FLNC truncation variants distributed across the FLNC gene. These truncation 
carriers had a prominent arrhythmogenic phenotype characteristic of arrhythmogenic DCM, 
family history of SCD, frequent RV involvement, and displayed no clinical signs of skeletal 
muscle involvement. As we previously reported, arrhythmogenic DCM patients have a 
higher risk for life-threatening ventricular arrhythmias and SCD, in particular when a family 
history of SCD is present, highlighting the importance of early identification of patients 
carrying FLNC truncation variants (13).
Filamins are large cytoskeletal actin cross-linking proteins that stabilize the actin filament 
networks and link them to the cell membrane by binding transmembrane proteins and ion 
channels (29). FLNC encodes a large protein (2,725 amino acids) primarily expressed in the 
cardiac and skeletal muscle that interacts with sarcomeric proteins in the Z-disc and the 
sarcolemma (6). Mutations in FLNC were initially reported to cause MFM (6), while cardiac 
involvement may have been noted, but not studied extensively. A study of German families 
with the p.Trp2710* founder mutation reported that 8 of 31 patients had LV hypertrophy, 
atrial fiutter, and right bundle branch block (30). More recent reports support FLNC 
involvement in a spectrum of cardiomyopathies, including HCM, RCM, and DCM, where 
arrhythmias, cardiac conduction disease, and SCD were also described (7,8) in the absence 
of skeletal muscle pathology (7–12). Similarly, our FLNC truncation carriers also exhibited 
no clinical evidence of skeletal muscle abnormalities. Our current report provides additional 
evidence of an arrhythmogenic DCM phenotype likely caused by FLNC truncation variants, 
including LV dysfunction, RV involvement, severe arrhythmias, and conduction disease.
All variants identified in our study are expected to lead to a truncated or absent FLNC 
protein. Our analysis of FLNC transcripts revealed that most (87.0%) were wildtype, 
suggestive of a haploinsufficiency model. This agrees with our previous investigation 
reporting that explanted heart tissue from a FLNC truncation carrier had reduced levels of 
FLNC protein compared with healthy control samples by Western blot, lending support for a 
haploinsufficiency mechanism of FLNC pathology (9). We also previously found that a 
reduction in flncb (ortholog of human FLNC) RNA expression in zebrafish results in 
structural and functional cardiac abnormalities (9), further supporting the theory that 
reduced FLNC expression may result in the observed cardiac dysfunctions.
We additionally found irregular and thickened Z-discs in the tissue of FLNC truncation 
carriers (Figures 4A to 4D). Similarly, in our flncb MO knockdown zebrafish model, the 
cardiac muscle ultrastructure displayed prominent Z-disc disarray and malformations, and in 
some instances the Z-disc was absent (9). Surprisingly, our current study did not find 
cytoplasmic protein aggregates in the heart, which have been described previously in FLNC-
associated patients with MFM (in muscle biopsies) as well as HCM and RCM patients (7,8). 
In these cases, accumulations of protein aggregates are believed to result from the inability 
of FLNC to dimerize and cross-link with actin at the C-terminal end of FLNC. The absence 
of FLNC protein aggregates in our study and in the series of Ortiz-Genga et al. (12), is again 
more in line with a haploinsufficiency model.
The highly arrhythmogenic phenotype and the pattern of biventricular subepicardial fibrosis 
and fatty infiltration seen in 2 siblings from family DNFDC057 is more reminiscent of 
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features previously described specifically in left-dominant arrhythmogenic cardiomyopathy 
and PLN R14del cardiomyopathy (31) rather than classical ARVC. For example, reduced 
junctional signal for desmoplakin, seen in both the heart and buccal mucosa in siblings from 
family DNFDC057, is more closely linked with biventricular involvement. Similarly, 
changes in the distribution of cell–cell junction proteins in the heart and buccal mucosa of 
these patients are more typical of left-dominant arrhythmogenic cardiomyopathy than 
classical ARVC. Interestingly, we also observed reduced signal for the membrane-associated 
guanylate kinase protein SAP97 in both the heart and buccal mucosa in 2 siblings from 
kindred DNFDC057. Such reduced SAP97 signal has been implicated in abnormal 
trafficking of ion channel proteins involved in channeling sodium and potassium ions, 
specifically related to regulating the INa, and IK1 currents, which help maintain normal 
cardiac ventricular resting membrane action potential (27). This may be relevant to the 
highly arrhythmogenic phenotype seen in our patients: reduced junctional signals for 
plakoglobin and Cx43 and translocation of GSK3β to cell–cell junctions are all features 
consistently seen in classical ARVC, but were not seen in our patients. Finally, although we 
have previously shown that buccal mucosa cells exhibit changes similar to those seen in the 
hearts of ARVC patients (24), studies here are the first to directly compare buccal cells and 
myocardium from the same patients. These results add further credence to the idea that 
changes in the heart of complex familial arrhythmia syndromes may also be seen in the 
buccal mucosa.
STUDY LIMITATIONS
Our study may be limited by the low frequency of FLNC truncations, the inability to 
perform extensive segregation analysis due to small family sizes, and an incomplete 
availability of DNA samples from biological members of FLNC truncation families. Efforts 
to recruit additional family members, especially reportedly affected individuals, have not 
been fruitful to date. In addition, cardiac tissue was only available from 1 family (2 siblings), 
which hinders our ability to systematically evaluate the effects of different variants on 
cardiac cellular structure and function. The presence of a variant in another DCM-related 
gene (SCN5A) in combination with the FLNC truncation variant in patient TSFDC043 I:1 
presents an additional confounding variable. Although all patients are routinely examined 
for muscle wasting, rigidity, muscle strength, and coordination, invasive skeletal muscle 
studies that may reveal more subtle pathology, such as electromyography and muscle biopsy, 
were not performed. Additional phenotypic characterization, such as with contrast-enhanced 
cardiac magnetic resonance, was also not done in our population. Finally, future studies are 
needed to elucidate how FLNC truncation variants lead to cardiomyocyte dysfunction and 
cardiac muscle disease.
CONCLUSIONS
Our report provides new evidence that FLNC truncation variants are associated with a severe 
arrhythmogenic DCM phenotype in the absence of overt skeletal muscle disease. FLNC 
should be included in DCM genetic testing panels, particularly when arrhythmias complicate 
the presenting phenotype. Additionally, patients with FLNC truncation variants should be 
clinically monitored for arrhythmias and considered for implantable cardioverter-
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defibrillators. Histological and ultrastructural analysis of heart muscle showed no protein 
aggregates as described in MFM, but instead showed biventricular subepicardial fibrofatty 
infiltration, Z-disc abnormalities, and redistribution of cell–cell junction proteins. We 
theorize that haploinsufficiency of FLNC (9) may disrupt its normal functions of cross-
linking actin filaments, connecting subsarcolemmal sarcomere Z-discs to the cell membrane 
and integrins, and connecting actin to cell–cell adhesion junctions in intercalated discs, to 
result in interference with the desmosomal/cell–cell junction pathway and manifest as a 
phenotypically arrhythmogenic cardiomyopathy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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DCM dilated cardiomyopathy
DNA deoxyribonucleic acid
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FLNC Filamin C
SK3β glycogen synthase kinase 3 beta
HCM hypertrophic cardiomyopathy
LV left ventricle/ventricular
MFM myofibrillar skeletal myopathy
RNA ribonucleic acid
RV right ventricle/ventricular
SAP97 synapse-associated protein 97
SCD sudden cardiac death
TEM transmission electron microscopy
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE
As the number of genes associated with DCM continues to increase, differences in 
clinical presentations are becoming recognized. Patients with FLNC truncation variants 
should be clinically monitored for arrhythmias and considered for implantable 
cardioverter-defibrillator devices.
TRANSLATIONAL OUTLOOK
DCM is a common cause of heart failure and life-threatening arrhythmias, and it is 
frequently caused by gene mutations. The whole spectrum of genetic determinants of 
DCM is still unknown: however, recently, a novel disease gene known to cause muscular 
dystrophy, filamin C, has been reported in human dilated cardiomyopathy and zebrafish 
models. Here, we report that FLNC truncating variants are not rare, are associated with a 
cardiac-restricted phenotype, are characterized by a high risk of life-threatening 
ventricular arrhythmias, and are a pathological cellular phenotype affecting the cell–cell 
adhesion structures, which partially overlaps with ARVC.
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FIGURE 1. Pedigrees of DCM Families With FLNC Truncating Variants Displaying an 
Arrhythmogenic Phenotype
(A) Squares indicate males, circles indicate females, slashes indicate deceased individuals, 
black shading indicates a dilated cardiomyopathy (DCM) phenotype, and vertical lines 
indicate history of heart disease. The arrows indicate the proband. Carriers (+) and 
noncarriers (−) of a FLNC truncation variant are shown. (B) Electrocardiogram of subject 
TSSDC130 (II:3) shows sustained ventricular tachycardia. (C) Electrocardiogram depicts 
nonsustained ventricular tachycardia from individual II:1 (family DNFDC057) (9).
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FIGURE 2. Structural Distribution of Truncating Variants in the Human FLNC Protein
Schematic of the FLNC immunoglobulin-like repeats labeled 1 to 24 using transcript 
NP_001449.3. Hinge 1 and 2 domains are labeled as H1 and H2, respectively. Red vertical 
lines indicate protein positions of the 6 FLNC truncation variants detected in our dilated 
cardiomyopathy (DCM) families. Black vertical lines represent previously reported 
hypertrophic cardiomyopathy (HCM) (7), restrictive cardiomyopathy (RCM) (8), DCM 
variants (12), and myofibrillar skeletal myopathies (MFM) (6) variants.
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FIGURE 3. Cardiac Tissue Analysis ofFLNC Truncation Variant Carrier From Family 
DNFDC057 (II:2)
(A) Trichrome staining of the left ventricle shows subepicardial interstitial and focal 
replacement fibrosis and fatty infiltration (circle) in areas containing degenerating cardiac 
myocytes. Scale bar = 200 μm. (B) Fatty infiltration and mild fibrosis are seen in the right 
ventricle. Scale bar = 100 μm.
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FIGURE 4. Electron Microscopy Images of Left Ventricular Cardiac Muscle From Family 
DNFDC057
(A) Representative images from individual II:2 show disarrayed Z-discs (white arrows). (B) 
Magnified image of the white box in A, showing a thickened Z-disc pattern. (C and D) 
Representative TEM images from individual II:1 exhibiting disarray of Z-discs (black 
arrows). No aggregates are seen in cardiac myocytes. Scale bars: (A) 1 μm, (B) 200 nm, (C 
and D) 1 μm.
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FIGURE 5. Immunohistochemistry of Left Ventricular Myocardial Tissue
Immunostaining of the explanted heart of patient DNFDC057-II:2 carrying the 
G1891Vfs61X FLNC truncation. (A) Immunoreactive signals for plakoglobin and connexin 
43 (Cx43) at intercalated discs are normal compared with control samples, whereas 
junctional signal for desmoplakin is reduced. N-cadherin is used as a tissue quality control 
and is normal in all samples. (B) SAP97 signal is depressed compared with control samples. 
GSK3β maintained its normal cytoplasmic distribution.
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FIGURE 6. FLNC in Cardiac Tissue
Immunohistochemical staining of FLNC does not show significant presence of aggregates in 
cardiomyocytes, and the weaker staining in the patient (C) suggests a reduced amount of 
FLNC protein compared with control subjects (A and B), as previously shown by western 
blot (9).
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FIGURE 7. Immunohistochemistry of Buccal Mucosa
Immunostaining of the buccal mucosa in patients DNFDC057-II:1 and II:2 shows normal 
signals for plakoglobin, and diminished signal for connexin 43 (Cx43), desmoplakin, and 
SAP97. E-cadherin staining is used as a cell quality control and is normal in all samples.
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